MESOBLAST LTD- SPON ADR (MESO) Fundamental Analysis & Valuation

NASDAQ:MESO • US5907174016

Current stock price

14.36 USD
-0.42 (-2.84%)
At close:
14.32 USD
-0.04 (-0.28%)
After Hours:

This MESO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. MESO Profitability Analysis

1.1 Basic Checks

  • MESO had negative earnings in the past year.
  • In the past year MESO has reported a negative cash flow from operations.
  • MESO had negative earnings in each of the past 5 years.
  • MESO had a negative operating cash flow in each of the past 5 years.
MESO Yearly Net Income VS EBIT VS OCF VS FCFMESO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • MESO has a better Return On Assets (-13.06%) than 80.92% of its industry peers.
  • MESO has a Return On Equity of -17.77%. This is amongst the best in the industry. MESO outperforms 83.24% of its industry peers.
Industry RankSector Rank
ROA -13.06%
ROE -17.77%
ROIC N/A
ROA(3y)-12.8%
ROA(5y)-13.09%
ROE(3y)-17.24%
ROE(5y)-17.42%
ROIC(3y)N/A
ROIC(5y)N/A
MESO Yearly ROA, ROE, ROICMESO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15

1.3 Margins

  • MESO's Gross Margin of 70.17% is amongst the best of the industry. MESO outperforms 80.92% of its industry peers.
  • In the last couple of years the Gross Margin of MESO has grown nicely.
  • The Profit Margin and Operating Margin are not available for MESO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y26.94%
MESO Yearly Profit, Operating, Gross MarginsMESO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. MESO Health Analysis

2.1 Basic Checks

  • MESO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MESO has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, MESO has more shares outstanding
  • The debt/assets ratio for MESO has been reduced compared to a year ago.
MESO Yearly Shares OutstandingMESO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
MESO Yearly Total Debt VS Total AssetsMESO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • MESO has an Altman-Z score of 3.52. This indicates that MESO is financially healthy and has little risk of bankruptcy at the moment.
  • MESO has a Altman-Z score of 3.52. This is in the better half of the industry: MESO outperforms 70.33% of its industry peers.
  • MESO has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
  • MESO has a Debt to Equity ratio of 0.11. This is in the lower half of the industry: MESO underperforms 63.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z 3.52
ROIC/WACCN/A
WACC9.54%
MESO Yearly LT Debt VS Equity VS FCFMESO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • MESO has a Current Ratio of 1.58. This is a normal value and indicates that MESO is financially healthy and should not expect problems in meeting its short term obligations.
  • MESO's Current ratio of 1.58 is on the low side compared to the rest of the industry. MESO is outperformed by 81.12% of its industry peers.
  • MESO has a Quick Ratio of 1.41. This is a normal value and indicates that MESO is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.41, MESO is not doing good in the industry: 81.70% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.41
MESO Yearly Current Assets VS Current LiabilitesMESO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. MESO Growth Analysis

3.1 Past

  • MESO shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.05%.
  • The Revenue has grown by 191.39% in the past year. This is a very strong growth!
  • MESO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.76% yearly.
EPS 1Y (TTM)5.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.95%
Revenue 1Y (TTM)191.39%
Revenue growth 3Y18.97%
Revenue growth 5Y-11.76%
Sales Q2Q%1526.81%

3.2 Future

  • Based on estimates for the next years, MESO will show a very strong growth in Earnings Per Share. The EPS will grow by 40.06% on average per year.
  • MESO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 121.89% yearly.
EPS Next Y56.53%
EPS Next 2Y46.6%
EPS Next 3Y46.13%
EPS Next 5Y40.06%
Revenue Next Year631.17%
Revenue Next 2Y218.46%
Revenue Next 3Y172.33%
Revenue Next 5Y121.89%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MESO Yearly Revenue VS EstimatesMESO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
MESO Yearly EPS VS EstimatesMESO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

3

4. MESO Valuation Analysis

4.1 Price/Earnings Ratio

  • MESO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • MESO is valuated quite expensively with a Price/Forward Earnings ratio of 29.36.
  • MESO's Price/Forward Earnings ratio is rather cheap when compared to the industry. MESO is cheaper than 92.49% of the companies in the same industry.
  • MESO's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.42.
Industry RankSector Rank
PE N/A
Fwd PE 29.36
MESO Price Earnings VS Forward Price EarningsMESO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MESO Per share dataMESO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • MESO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • MESO's earnings are expected to grow with 46.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.6%
EPS Next 3Y46.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MESO Dividend Analysis

5.1 Amount

  • MESO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MESO Fundamentals: All Metrics, Ratios and Statistics

MESOBLAST LTD- SPON ADR

NASDAQ:MESO (3/20/2026, 8:08:20 PM)

After market: 14.32 -0.04 (-0.28%)

14.36

-0.42 (-2.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)N/A
Inst Owners16.09%
Inst Owner Change11.2%
Ins Owners22.8%
Ins Owner Change0%
Market Cap1.85B
Revenue(TTM)17.20M
Net Income(TTM)-102.14M
Analysts82
Price Target18.03 (25.56%)
Short Float %3.35%
Short Ratio11.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.32%
PT rev (3m)-10.97%
EPS NQ rev (1m)-1.47%
EPS NQ rev (3m)-0.9%
EPS NY rev (1m)-170.47%
EPS NY rev (3m)-168.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)10.05%
Revenue NY rev (3m)10.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 29.36
P/S 107.74
P/FCF N/A
P/OCF N/A
P/B 3.22
P/tB 314.89
EV/EBITDA N/A
EPS(TTM)-0.85
EYN/A
EPS(NY)0.49
Fwd EY3.41%
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0.13
BVpS4.45
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.06%
ROE -17.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.17%
FCFM N/A
ROA(3y)-12.8%
ROA(5y)-13.09%
ROE(3y)-17.24%
ROE(5y)-17.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y26.94%
F-Score6
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 6.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 1.41
Altman-Z 3.52
F-Score6
WACC9.54%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)4.02%
Cap/Sales(5y)7.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.95%
EPS Next Y56.53%
EPS Next 2Y46.6%
EPS Next 3Y46.13%
EPS Next 5Y40.06%
Revenue 1Y (TTM)191.39%
Revenue growth 3Y18.97%
Revenue growth 5Y-11.76%
Sales Q2Q%1526.81%
Revenue Next Year631.17%
Revenue Next 2Y218.46%
Revenue Next 3Y172.33%
Revenue Next 5Y121.89%
EBIT growth 1Y-23.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100.54%
EBIT Next 3Y102.96%
EBIT Next 5Y101.36%
FCF growth 1Y-2.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.92%
OCF growth 3YN/A
OCF growth 5YN/A

MESOBLAST LTD- SPON ADR / MESO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MESOBLAST LTD- SPON ADR (MESO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MESO.


What is the valuation status for MESO stock?

ChartMill assigns a valuation rating of 3 / 10 to MESOBLAST LTD- SPON ADR (MESO). This can be considered as Overvalued.


Can you provide the profitability details for MESOBLAST LTD- SPON ADR?

MESOBLAST LTD- SPON ADR (MESO) has a profitability rating of 3 / 10.